$ALNY Rises 3.5% After Update Tied to Q2 2026 Results

Alnylam ($ALNY) rose 3.5% on Aug 19, 2026 after an update tied to its second quarter 2026 financial results and a reset to expectations for its TTR business.

What Alnylam announced

Alnylam discussed its second quarter 2026 financial results. In that update, the company said it “lowered our TTR product sales guidance for full-year 2026” based on what it’s learning from the initial phase of its launch in the evolving ATTR-CM market. Management pointed to “the normalization of growth in second line volume” after what it described as pent-up demand from patients who had been waiting for a new therapy. As part of that reset, Alnylam lowered its total projected TTR net product revenues by approximately $200 million.

What it means for Alnylam

The key takeaway is that Alnylam is framing early commercial traction as front-loaded, with demand cooling as the market moves past an initial backlog. That kind of “normalization” language suggests the company is recalibrating how quickly it expects adoption to build in later-line use, at least in the near term. The reduced projection for TTR net product revenues could shape how investors think about the pace of growth for the TTR franchise through the rest of 2026. It also underscores how launch dynamics in ATTR-CM can change quickly as early adopters and waiting patients get treated.

How the stock reacted

Shares moved higher in the minutes and hours after the news.

Window	Move
5 min	+1.1%
10 min	+1.4%
30 min	+2.3%
1 hour	+1.5%
end of day	+3.5%

On a market-adjusted basis, $ALNY outperformed the SPY by +3.6% on Aug 19, 2026.